iShares S&P Global Healthcare ETF (ASX:IXJ)
The iShares IXJ ETF provides investors with a targeted exposure to over 100 global healthcare companies. This includes companies in the pharmaceutical, biotechnology, and medical device space.
IXJ ETF review
IXJ share price and fees
IXJ fees
Analyst report
Fee comparison
What does the IXJ ASX ETF invest in?
IXJ invests in a portfolio of global healthcare companies, including leading brands like Johnson & Johnson, CSL and Glaxosmithkline. Trying to replicate this exposure to healthcare stocks yourself would be time-consuming and expensive, so IXJ could be a solution for investors looking for a targeted exposure to this sector.
What do investors use the IXJ ETF for?
IXJ could be used by investors to gain a tactical exposure to the global healthcare sector, and has a strong geographical exposure to the US market. This ETF aims to track the S&P Global 1200 Healthcare Sector Index, before fees and expenses.
How to buy the IXJ ETF
A portfolio FULL of our best ETF ideas
Click the button to discover how you can create one account and get an automated professionally managed ETF portfolio.
IXJ investor starter pack
IXJ literature
IXJ holdings
ASX: IXJ’s dividend 2021
When does IXJ pay a dividend?
IXJ dividend reinvestment plan (DRP)
Warnings we apply to the IXJ ETF
IXJ tax domicile
IXJ ETF registry
Fund issuer
International shares sector data
How IXJ compares:
Latest ETF News
*The warnings on this page are applied by our ETF research team. Please know that these warnings are based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.
The Best ETF in Australia?
We’ve found the ONE ETF that could rule them all…
Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click?
Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF.
Best of all: The report is totally free and will be sent via email.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian-owned.